Novartis Pharmaceuticals said it has won FDA approval for its Amturnide pill, which combines three drugs into one pill for people being treated for high blood pressure.

The announcement came during the same week that the Swiss-based company’s Vaccines and Diagnostics operation announced that it will add a development lab and pilot plant at the site of its pandemic and seasonal flu production facility in Wake County, N.C., and add 100 jobs.

Amturnide combines Novartis’s Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

“The FDA approval of Amturnide provides an important treatment option to help address the complex needs of high blood pressure patients,” said Andre Wyss, Novartis Pharmaceuticals president. “This approval emphasizes our commitment to cardiovascular research and to developing innovative and effective treatments for patients who have not reached their blood pressure goal.”

Get the latest news alerts: Follow LTW at Twitter.